Core Viewpoint - Skye Bioscience, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in James Hardie Industries plc. ("James Hardie Industries plc." or the "Company") (NYSE: JHX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of James Hardie Industries plc. investors who were adversely affected by alleged securities fraud between May 20, 2025 and August 18, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Firefly Aerospace Inc. ("Firefly Aerospace Inc." or the "Company") (NASDAQ: FLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Firefly Aerospace Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired: (a) Firefly ...

Core Viewpoint - A class action securities lawsuit has been filed against Freeport-McMoRan Inc. alleging securities fraud affecting investors between February 15, 2022, and September 24, 2025 [1][2] Group 1: Allegations - The lawsuit claims that Freeport-McMoRan did not ensure adequate safety at the Grasberg Block Cave mine in Indonesia [2] - It is alleged that the lack of safety measures posed a heightened risk of worker fatalities [2] - The complaint states that these safety issues led to undisclosed regulatory, litigation, and reputational risks [2] - As a result, statements made by the defendants regarding Freeport-McMoRan's business and operations were materially false and misleading [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 12, 2026, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sprouts Farmers Market, Inc. on behalf of investors who acquired its securities during the specified Class Period, following disappointing financial results and guidance cuts [1][2]. Financial Performance - On October 29, 2025, Sprouts reported third-quarter results showing comparable-store sales growth of 5.9%, which was below the company's prior guidance [2]. - The company revised its full-year comparable store growth expectations to flat to 2%, attributing the results to challenging year-on-year comparisons and signs of a softening consumer [2]. - Following the announcement, Sprouts' stock price dropped by $27.3, or 26.1%, closing at $77.25 per share on October 30, 2025, resulting in significant losses for investors [2]. Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include: - Misrepresentation of the resilience of Sprouts' customer base to macroeconomic conditions [3]. - Inaccurate portrayal of the impact of "trade-down" dynamics on sales [3]. - Overstated guidance on comparable sales and growth trajectory, which did not reflect the actual slowdown in sales growth [3]. - Positive statements made by the defendants were misleading and lacked a reasonable basis [3].

New York, New York--(Newsfile Corp. - December 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-act ...

New York, New York--(Newsfile Corp. - December 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc- ...

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018 [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - The complaint alleges that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - The company stated on May 20, 2025, that it was experiencing "normal stock levels" and expected performance to align with projections, which was later contradicted by actual sales data [5]. Group 4: Stock Performance - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, revealing that customers were destocking inventory, which led to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 [6]. Group 5: Executive Changes - On November 17, 2025, it was announced that Rachel Wilson had decided to step down from her role as CFO [7].